After going ‘crazy’ over the science, Merck signs up a new partner in the hunt for an HIV cure

Max Gelman

Senior Editor

Less than a year after inking a $100 million licensing deal with German giant Bayer, Dewpoint Therapeutics has scored another big-time contract, this time with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After going ‘crazy’ over the science, Merck signs up a new partner in the hunt for an HIV cure

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

FDA approves first drug to treat ultra-rare lipid storage disease

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA says Ozempic, Wegovy shortage is over

Trump blog: Judge extends nationwide block on NIH payment cuts

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Af­ter go­ing ‘crazy’ over the sci­ence, Mer­ck signs up a new part­ner in the hunt for an HIV cure

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

After going ‘crazy’ over the science, Merck signs up a new partner in the hunt for an HIV cure